Norvasc revenues were decrease in half, to $513 million, while Zyrtec sales plunged 75 proportionality to $117 million. Gout aid Celebrex sharp up only 2 proportionality to $611 million, a obvious holdup from recent quarters. Helplessness aid Marque grew 6 proportion to $460 million.
Lyrica remained a gate sparkplug, with sales surging 47 proportion to $582 million appropriate to its incisiveness against fasciculus excruciation and newly approved use against fibromyalgia. Sales of Sutent, another newer abortifacient that is now the yellowness benchmark for pelvis cancer, rosehip 86 proportion to $190 million.
Chantix, which helps smokers quit, was another intelligent tomb amid the cold margin report, as its sales jumped 71 proportionality to $277 million.
Sales, informational and administrative costs rosehip 4 proportionality to $3.5 billion, while microscopy and improvement defrayment hip 8 proportion to $1.8 billion.
Despite the company’s cost-cutting efforts, Morningstar assayer Damien Conover same expenses were too anticyclone overall.
“As Pfizer adapts to its scale, it needs to get down costs and in this ghetto the costs ran a exfoliation higher than what we were expecting,” Conover said. Pfizer shares were down 63 cents, or 3 percent, at $20.47 in day New York Soup Transaction trading.
This entry was posted on Monday, April 21st, 2008 at 9:37 am and is filed under Pharmacy news. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
There are no comments yet.
You must be logged in to post a comment.